Skip to main content

Table 4 Management of advanced HIV disease

From: Prevalence, predictors, and management of advanced HIV disease among individuals initiating ART in Senegal, West Africa

 

N (%)

ART

 Components of ART regimena

  NRTI backbone

   TDF + 3TC or FTC

160 (95.2)

   AZT + 3TC or FTC

8 (4.8)

  EFV-based regimenb

141 (83.9)

  NVP-based regimen

3 (1.8)

  Lop/rit-based regimenc

21 (12.5)

  Triple NRTI regimen using ABC

3 (1.8)

 Number of days between diagnosis and initiation of ART, median (IQR)

13.0 (6.0-26.5)

 ART started within ≤7 days of diagnosisd

  Among all subjects

42 (33.9)

  Among those with advanced disease

29 (37.7)

Co-trimoxazole

 Among all subjectse

83 (52.9)

 Among those with CD4 ≤350 cells/mm3 OR stage 3 or 4 diseasef

77 (64.7)

IPT

 No TB symptoms presentg

77 (46.4)

  Active extra-pulmonary TB

4 (5.2)

  Eligible for IPT: No TB screening symptoms or active TB

73 (44.0)

   INH prescription providedh

1 (1.4)

 TB symptoms present

89 (53.6)

  Diagnostic evaluation performed

35 (39.3)

  Diagnostic evaluation negativei

25 (71.4)

Fluconazole

 CD4 <100 and neurological symptoms present

7 (5.3)

 CD4 <100 and no neurological symptoms presentj

46 (34.6)

  CrAg screening

0 (0)

  Fluconazole prescription provided

0 (0)

  1. aRegimen available for 168 subjects
  2. bIncludes 1 HIV-2 infected subject
  3. cIncludes 18 HIV-2 infected subjects, 1 dually infected subject receiving TB treatment during an ABC stock-out, and 2 HIV-1 infected subjects
  4. dExcluding those with active TB or CM
  5. eData available for 157 subjects
  6. fData available for 151 subjects, of which 119 met criteria
  7. gData available for 166 subjects
  8. hINH provided for 2 weeks
  9. iEligibility for IPT in this scenario is dependent on clinical presentation and likelihood of TB
  10. jAmong non-pregnant subjects ≥18 years of age. Data available for 133 subjects